Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CNTG 
Centogene B V (CNTG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/11/2025: CNTG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.52
1 Year Target Price $1.52
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.69% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.43M USD | Price to earnings Ratio - | 1Y Target Price 1.52 |
Price to earnings Ratio - | 1Y Target Price 1.52 | ||
Volume (30-day avg) 1 | Beta -0.67 | 52 Weeks Range 0.01 - 0.35 | Updated Date 08/24/2025 |
52 Weeks Range 0.01 - 0.35 | Updated Date 08/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.39 |
Earnings Date
Report Date 2025-09-03 | When - | Estimate - | Actual - |
Profitability
Profit Margin -73.21% | Operating Margin (TTM) -63.29% |
Management Effectiveness
Return on Assets (TTM) -26.76% | Return on Equity (TTM) -1375.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 70012544 | Price to Sales(TTM) 0.19 |
Enterprise Value 70012544 | Price to Sales(TTM) 0.19 | ||
Enterprise Value to Revenue 1.31 | Enterprise Value to EBITDA -1.58 | Shares Outstanding 29000100 | Shares Floating 11780726 |
Shares Outstanding 29000100 | Shares Floating 11780726 | ||
Percent Insiders 4.57 | Percent Institutions 66.89 |
Upturn AI SWOT
Centogene B V
Company Overview
History and Background
Centogene B V was founded in 2006. It is a commercial-stage company focused on rare disease diagnostics and drug development. Initially focused on diagnostics, it has expanded into therapeutic development. Centogene went public in 2019.
Core Business Areas
- Diagnostics: Offers genetic testing and analysis for a wide range of rare diseases, including exome and genome sequencing.
- Pharmaceutical: Developing therapies for rare diseases based on insights from its extensive database of genetic and clinical data.
- Bio/Pharma Services: Provides specialized services to biopharmaceutical companies, supporting their drug development efforts.
Leadership and Structure
The leadership team consists of experienced professionals in the fields of genetics, pharmaceuticals, and business. The organizational structure includes departments for diagnostics, research & development, commercial operations, and administration.
Top Products and Market Share
Key Offerings
- CentoXome: Exome sequencing service for rare disease diagnosis. Competitors include Invitae (NVTA), GeneDx, and Quest Diagnostics (DGX).
- CentoGenome: Genome sequencing service. Competitors include Illumina (ILMN), Veritas Genetics, and Ambry Genetics. Market share data not readily available publicly.
- Bio/Pharma Services: Provides specialized services to biopharmaceutical companies, supporting their drug development efforts.Competitors include Charles River Laboratories (CRL), LabCorp (LH), and WuXi AppTec. Market share data not readily available publicly.
Market Dynamics
Industry Overview
The rare disease diagnostics and therapeutics market is growing, driven by increasing awareness, advancements in genetic sequencing technology, and the development of targeted therapies.
Positioning
Centogene is positioned as a leader in rare disease diagnostics, with a large database of genetic and clinical data. Its competitive advantage lies in its expertise in rare disease genetics and its integrated approach to diagnostics and therapeutics.
Total Addressable Market (TAM)
The global rare disease diagnostics market is projected to reach billions of dollars. Centogene is positioned to capture a significant portion of this market with its comprehensive testing portfolio and growing therapeutic pipeline.
Upturn SWOT Analysis
Strengths
- Extensive rare disease database
- Integrated diagnostics and therapeutics approach
- Strong expertise in genetics
- Global presence
Weaknesses
- Reliance on external funding
- Competition from larger diagnostic companies
- Potential regulatory challenges
- Limited therapeutic pipeline compared to larger pharmaceutical companies.
Opportunities
- Expanding therapeutic pipeline
- Strategic partnerships with pharmaceutical companies
- Increasing awareness of rare diseases
- Growth in emerging markets
Threats
- Competition from established diagnostic and pharmaceutical companies
- Changes in regulatory environment
- Economic downturn
- Pricing pressure
Competitors and Market Share
Key Competitors
- NVTA
- DGX
- ILMN
Competitive Landscape
Centogene faces strong competition from larger, more established diagnostic and pharmaceutical companies. Its competitive advantage lies in its specialized expertise in rare disease genetics.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by increased adoption of genetic testing for rare diseases. However, financial results have been volatile.
Future Projections: Future growth is expected to be driven by the development and commercialization of new therapies. Analyst estimates are currently uncertain.
Recent Initiatives: Recent initiatives include expanding the therapeutic pipeline and securing strategic partnerships.
Summary
Centogene is a specialized company focused on rare disease diagnostics and therapeutics, leveraging a substantial database. It faces competition and relies on external funding. The company needs to efficiently manage finances while expanding its therapeutic development. Its future depends on successful therapeutic development and strategic partnerships to capitalize on its unique market position. Financial instability poses a risk.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data is based on publicly available information and estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Centogene B V
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-11-07 | CEO & Member of Management Board Ms. Kim Stratton | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 384 | Website https://www.centogene.com |
Full time employees 384 | Website https://www.centogene.com | ||
Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports. In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors. The company was founded in 2006 and is headquartered in Rostock, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.